Beyond Herceptin and Gleevec

被引：69

作者：

Fischer, OM ^{[1
]}

Streit, S ^{[1
]}

Hart, S ^{[1
]}

Ullrich, A ^{[1
]}

机构：

[1] Max Planck Inst Biochem, Dept Biol Mol, D-82152 Martinsried, Germany

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2003年 / 7卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(03)00082-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Identification of the key role of protein kinases as potential oncoproteins has led to the emergence of a new era of target-directed therapies. Among a variety of novel therapeutic strategies two have shown the most promise and led to a variety of therapeutic agents in clinical development. One approach utilises humanised monoclonal antibodies generated against the extracellular domain of transmembrane protein kinases. The second approach is the generation of small molecule ATP analogues targeting the kinase domain itself. The approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumours are the first examples of gene-based cancer drugs and represent the first example of a novel strategy in anti-cancer therapy.

引用

页码：490 / 495

页数：6

共 47 条

[1] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].

Alroy, I ;

Yarden, Y .

FEBS LETTERS, 1997, 410 (01) :83-86

[2] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[3] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[4]

CHAZIN VR, 1992, ONCOGENE, V7, P1859

[5] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[6] Agents targeting Ras signaling pathway [J].

Dancey, JE .

CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (25) :2259-2267

[7] CLOSE SIMILARITY OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND V-ERB-B ONCOGENE PROTEIN SEQUENCES [J].

DOWNWARD, J ;

YARDEN, Y ;

MAYES, E ;

SCRACE, G ;

TOTTY, N ;

STOCKWELL, P ;

ULLRICH, A ;

SCHLESSINGER, J ;

WATERFIELD, MD .

NATURE, 1984, 307 (5951) :521-527

[8] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[9]

FIEDLER WM, 2001, P AN M AM SOC CLIN, V20, pA288

[10]

Fukuoka M., 2002, P AN M AM SOC CLIN, V21, p298a

← 1 2 3 4 5 →